KARACHI: Dow University of Health Sciences (DUHS) medical experts on Monday claimed that they have created a drug to treat patients suffering from the coronavirus disease.
As per the details, medical experts from DUHS claimed that Intravenous Immunoglobulin (IVIG) can cure COVID-19 patients.
Professor Muhammad Saeed Qureshi, a member of the research team, said that Intravenous Immunoglobulin is a great development in the fight against novel coronavirus.
He said the globulin was manufactured with purified antibodies, obtained from the recovered coronavirus patients.
“This way of treatment is safe, low risk and highly effective against coronavirus. Through this method, Immunoglobulin is prepared after separation of antibodies found in the blood of a recovered patient,” the statement said, pointing out that this form of treatment has been approved by US Food and Drug Administration.
Calling its effort “a ray of hope in this time of crisis”, the university added that the research team, led by Dr Shaukat Ali, developed this form of treatment after it was able to collect the first blood sample from an infected patient in March.
“The team managed to isolate antibodies from the blood sample chemically, purified it and later concentrated these antibodies using ultrafiltration techniques that remove the remaining unwanted materials from the final product,” the statement added, explaining the technique behind the potential treatment.
The university displayed confidence in the efficacy of its treatment by arguing that the Covid-19 strain currently infecting Pakistanis only has a “few mutations” and therefore local IVIG from infected patients holds the potential to provide an extremely potent form of immunisation against Covid-19 for Pakistanis.
Last week, researchers from the university had discovered that certain variants of a human gene may offer resistance against the novel coronavirus, also known as SARS-CoV-2.
According to their findings, which were published in the Journal of Medical Virology, two variants of the ACE2 (angiotensin I converting enzyme 2) gene — that has been established as the functional receptor for the novel coronavirus — may make a person more resistant to the infection.
On April 9, the Drug Regulatory Authority of Pakistan (DRAP) allowed clinical trials of blood plasma therapy to treat coronavirus patients in the country.
Plasma, the fluid in blood teeming with antibodies post-illness, has already proven effective in small studies to treat infectious diseases including Ebola and SARS.
The announcement was made by Special Assistant to PM on Health, Dr Zafar Mirza, here on Monday. “The DRAP has also approved local manufacturing of the raw material of the anti-malarial drug, chloroquine.”
